Phase 3 Study of Tecentriq in Advanced Stage Ovarian Cancer Fails to Meet its Main Goal of Progression-Free Survival

The addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin failed to meet one of the phase 3 IMagyn050 trial’s main goals of improving progression-free survival, or the time from the start of treatment until disease worsened, in the front-line treatment setting of newly diagnosed advanced stage ovarian cancer, according to a press release from the drug’s manufacturer.

The updated data, however, shows that the safety profile for Tecentriq in this study was consistent with available safety data regarding this combination.

“Ovarian cancer remains one of the most aggressive cancers and is difficult to treat in its advanced stages,” Dr. Levi Garraway, chief medical office and head of Global Product Development at Roche, said in the release. “While we are disappointed by these results, we remain committed to improving outcomes for women living with this disease and are pleased that Avastin remains a key component in the treatment of front-line ovarian cancer.”

The multicenter, randomized, double-blind study is assessing the safety and efficacy of adding Tecentriq to Avastin, paclitaxel and carboplatin compared to placebo in combination with those chemotherapy agents in women with stage 3 or 4 ovarian cancer who are receiving neoadjuvant or adjuvant treatment.

Measuring progression-free survival and overall survival were the main goals of the study. Although the study failed to meet its goal of progression-free survival, overall survival data are currently not yet available, and follow-up will continue until the next planned analysis.

Additional goals of the study include objective response rate, or the proportion of patients who experienced complete or partial responses to treatment, as well as safety and patient-reported improvement in abdominal pain and bloating.

For more information on ovarian cancer updates, research and education, visit/click here.